Evidence map›Paper›PMID 27245161›Full record

ArticleBMC systems biology2016

A rule-based model of insulin signalling pathway.

Barbara Di Camillo, Azzurra Carlon, Federica Eduati, Gianna Maria Toffolo

Abstract read
In one paragraph

Article in BMC systems biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Review
  3. The Potential ofDrug design, development and therapy · 2026
    Review
  4. Review
  5. Exploring the Biological Effects of Anti-Diabetic Vanadium Compounds in the Liver, Heart and Brain.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024
    Review
  6. In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023
    Article
  7. Review
  8. Insulin Signaling Pathway Model in Adipocyte Cells.Current pharmaceutical design · 2023
    Article
  9. Review
  10. Insulin and cancer: a tangled web.The Biochemical journal · 2022
    Review
  11. Article
  12. Continuous variable responses and signal gating form kinetic bases for pulsatile insulin signaling and emergence of resistance.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  13. Article
  14. NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2.Canadian journal of gastroenterology & hepatology · 2021
    Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Barbara Di CamilloDepartment of Information Engineering, University of Padova, Via Gradenigo 6A, Padova, 35131, Italy.
Azzurra CarlonDepartment of Information Engineering, University of Padova, Via Gradenigo 6A, Padova, 35131, Italy.
Federica EduatiDepartment of Information Engineering, University of Padova, Via Gradenigo 6A, Padova, 35131, Italy.
Gianna Maria ToffoloDepartment of Information Engineering, University of Padova, Via Gradenigo 6A, Padova, 35131, Italy. toffolo@dei.unipd.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe insulin signalling pathway (ISP) is an important biochemical pathway, which regulates some fundamental biological functions such as glucose and lipid metabolism, protein synthesis, cell proliferation, cell differentiation and apoptosis. In the last years, different mathematical models based on ordinary differential equations have been proposed in the literature to describe specific features of the ISP, thus providing a description of the behaviour of the system and its emerging properties. However, protein-protein interactions potentially generate a multiplicity of distinct chemical species, an issue referred to as "combinatorial complexity", which results in defining a high number of state variables equal to the number of possible protein modifications. This often leads to complex, error prone and difficult to handle model definitions.

resultsIn this work, we present a comprehensive model of the ISP, which integrates three models previously available in the literature by using the rule-based modelling (RBM) approach. RBM allows for a simple description of a number of signalling pathway characteristics, such as the phosphorylation of signalling proteins at multiple sites with different effects, the simultaneous interaction of many molecules of the signalling pathways with several binding partners, and the information about subcellular localization where reactions take place. Thanks to its modularity, it also allows an easy integration of different pathways. After RBM specification, we simulated the dynamic behaviour of the ISP model and validated it using experimental data. We the examined the predicted profiles of all the active species and clustered them in four clusters according to their dynamic behaviour. Finally, we used parametric sensitivity analysis to show the role of negative feedback loops in controlling the robustness of the system.

conclusionsThe presented ISP model is a powerful tool for data simulation and can be used in combination with experimental approaches to guide the experimental design. The model is available at http://sysbiobig.dei.unipd.it/ was submitted to Biomodels Database ( https://www.ebi.ac.uk/biomodels-main/ # MODEL 1604100005).

Indexed as

Models, BiologicalSignal TransductionBinding SitesInsulinIntracellular SpacePhosphorylationProtein Interaction MappingProtein TransportInsulinInsulin signalling pathwayParametric sensitivity analysisRule-based modellingSystem robustness

Identifiers

PMID27245161
PMCPMC4888568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.